←
Aaron Edwards3,252 posts
Aaron Edwards avatar

Aaron Edwards

@aedwards02

Building noise-cancelling headphones for cell therapies @KiraGenBio starting with glioblastoma @HarvardHBS • @BeamTx • @BluebirdBio

◷ Joined March 2009▧ 101 Photos and videos
Aaron Edwards avatar
Aaron Edwards@aedwards02·10 Nov 2025

This is why we built @KiraGenBio. Base editing made CAR-T possible for patients like Alyssa, CURED of T-cell leukemia after every other option failed. We built the U.S. version at @BeamTx. Help us make more stories like Alyssa’s for patients with GBM and other solid tumors!

60 Minutes@60Minutes10 Nov 2025

After leukemia treatments failed, Alyssa Tapley, at age 13, was told she would die. Then, doctors tried an experimental gene-edited therapy. She became the first human to try the treatment made possible by U.S. federal funding. Now 16, she’s cancer-free and planning her future. cbsn.ws/4ou0OMt

1:30
Aaron Edwards avatar
Aaron Edwards@aedwards02·Nov 11

So happy to hear about this launch. Go get’m @sahir_raoof!

So excited to share more about what I have been up to. @ProximalVC is a first check fund that loves to partner with founders before incorporation to support ideation and initial GTM strategy. If you’re building the systems that make discovery smarter, trials faster, manufacturing more resilient, supply chains more transparent or commercial execution more precise - please reach out!

Aaron Edwards avatar
Aaron Edwards@aedwards02·Oct 31

We should be more careful as scientists about how we frame these tragic patient deaths. Gene editing did not kill this patient. A severe immune reaction to the AAV delivery vehicle did. Many people will only see this post and never read the paper. That distinction matters.

This tweet is unavailable

Jake Becraft avatar
⟳ Aaron Edwards retweeted
Jake Becraft@DrSynbio·Oct 30

We currently have more great ideas than we can realistically test in every indication they are promising. We need cheaper and faster clinical trial execution and interpretation. AI can massively expand this but only if we fix the fundamental bottlenecks in our regulatory process.

AI can make drug discovery cheaper, but a promising drug candidate can still become a very expensive failure. As AI gives us more candidates, knowing which ones deserve years of clinical work and serious capital becomes even more valuable. Those are consequential calls, and a longer pipeline doesn’t make them any easier. I’d like to see the same ambition we’re bringing to discovery applied to shortening clinical development and regulatory review. Saving time at the beginning should push us to tackle the years that follow. I’m encouraged by how quickly the science is advancing. But the patient waiting for treatment needs that science to become an approved medicine they can actually use.

Aaron Edwards avatar
Aaron Edwards@aedwards02·Oct 28

AI makes the one-person biotech possible. Early capital makes it real. If we want more stories like Cody’s, investors need to back founders before there’s a full team, a polished academic data package, or a Nobel lab pedigree. The biotech funding playbook needs to evolve, too.

Surprise 1: Anthropic acquired a one-person biotech . . . Surprise 2: that person is me Surprise 3: I’m here to tell you all about it Yes, this is what you think it is; after 6 yrs of increasingly loose anonymity: the Professor Oak reveal post …and yes, it has gotten so boring around here that I’m literally doxxing myself to spice up the timeline ------- Ok, allow me to introduce myself. My name is Cody Tranbarger. I mostly tweet, but occasionally find time to dabble in drug dev & starting/building biotechs. My past lives span the VC, crossover, startup continuum; Prof Oak has been my way of keeping a digital foot in those worlds, despite having my physical feet planted elsewhere. The past 18 mo, ‘elsewhere’ was Mithril Medicine, a co. I founded to develop bsAbs for LAMA2-CMD & other ECM-related genetic diseases. Mithril was born out of hands-on building with @MikeNGladstone, @JasonPaulRhodes, @LifeSciVC, & team @atlasventure. Somehow, I made enough half-decent calls along the way (even a broken clock is right twice a day, eh?) to convince them Mithril/I warranted a small seed. While I can hardly rationalize such an outrageously cavalier bet, I’m grateful for it, & I'd partner with Atlas again in a heartbeat. In typical AV fashion, Mithril’s primordial form was virtual, decentralized, & ultra-lean. This stage tends to be short-lived, but for Mithril, it worked surprisingly well, for surprisingly long, thanks in part to the rapid maturation of the AI tools I used liberally. Eventually, Mithril became a bit of an experiment itself - to find the upper bound of how far it could scale as a single operator + a bunch of Claude (+ a stellar bench of part-time consultants). In parallel, I started spending time with @nc_frey, @an1lam, & @CoefficientBio team; and promptly experienced, for the 1st time, AI at the frontier. Soon thereafter, Mithril stopped looking like an experiment, & started looking like a preview of an entirely new operating model. From that spark came “Pipeline-in-a-Person.” The idea immediately resonated when we shared it here back in April; and it was central to the shared vision that led to Anthropic’s acquisition of Mithril, & my joining the team. Why join Anthropic? Three reasons. (1) For Mithril, the programs continue, with more resources & infrastructure behind them, and as much Claude as I can put to work. (2) For me, the chance to start several more programs, & find out how many one person can actually run in parallel - an almost unprecedented luxury for a curious drug hunter. (3) For our mission, a path to institutionalize & scale this new way of working, then put it in the hands of all of biopharma, all over the world - which, candidly, I find the most energizing. Will AI x Bio cure diseases? Unequivocally yes, imo… but not by the route that gets the most airtime. Rather than timeline acceleration & compression, I see orchestration & parallelization as today's low-hanging fruit. Most drug hunters see a handful of go/no-go calls in a career, & spend entirely too much of the rest trading emails (my inbox can attest). Give them the bandwidth to run several programs at once, and the time to focus on scientific judgment, and I’m willing to bet they’ll make better calls. And at scale, better calls translate to more drugs, higher hit rates, broader patient impact, & likely, a disease or 10 or 100 cured. I couldn't be more excited to build toward that future @AnthropicAI. Finally, a heartfelt thank you to BioTwitter/X. The end of anonymity is bittersweet, but if anyone’s earned a proper introduction, you all have. It’s difficult to overstate how much this app has done for me: a decade of education, plenty of friends, many job opportunities, several mentors, a few investors, even a co-founder (fmr). It was the generosity of this community that inspired me to start posting 6 years ago, after just as many years lurking. I hope I’ve been able to pay it forward, in my own small way. But, to be clear, Prof Oak isn’t going anywhere. Same beat, same themes, and now, a front-row seat to drug development at the frontier. Stay tuned for dispatches from the trenches; and remember... Gotta Cure 'Em All

Aaron Edwards avatar
Aaron Edwards@aedwards02·Oct 27

BIG CONGRATS in store for my @HarvardHBS biotech MS/MBA ride or die, Cody Tranbarger! What a champ.

Surprise 1: Anthropic acquired a one-person biotech . . . Surprise 2: that person is me Surprise 3: I’m here to tell you all about it Yes, this is what you think it is; after 6 yrs of increasingly loose anonymity: the Professor Oak reveal post …and yes, it has gotten so boring around here that I’m literally doxxing myself to spice up the timeline ------- Ok, allow me to introduce myself. My name is Cody Tranbarger. I mostly tweet, but occasionally find time to dabble in drug dev & starting/building biotechs. My past lives span the VC, crossover, startup continuum; Prof Oak has been my way of keeping a digital foot in those worlds, despite having my physical feet planted elsewhere. The past 18 mo, ‘elsewhere’ was Mithril Medicine, a co. I founded to develop bsAbs for LAMA2-CMD & other ECM-related genetic diseases. Mithril was born out of hands-on building with @MikeNGladstone, @JasonPaulRhodes, @LifeSciVC, & team @atlasventure. Somehow, I made enough half-decent calls along the way (even a broken clock is right twice a day, eh?) to convince them Mithril/I warranted a small seed. While I can hardly rationalize such an outrageously cavalier bet, I’m grateful for it, & I'd partner with Atlas again in a heartbeat. In typical AV fashion, Mithril’s primordial form was virtual, decentralized, & ultra-lean. This stage tends to be short-lived, but for Mithril, it worked surprisingly well, for surprisingly long, thanks in part to the rapid maturation of the AI tools I used liberally. Eventually, Mithril became a bit of an experiment itself - to find the upper bound of how far it could scale as a single operator + a bunch of Claude (+ a stellar bench of part-time consultants). In parallel, I started spending time with @nc_frey, @an1lam, & @CoefficientBio team; and promptly experienced, for the 1st time, AI at the frontier. Soon thereafter, Mithril stopped looking like an experiment, & started looking like a preview of an entirely new operating model. From that spark came “Pipeline-in-a-Person.” The idea immediately resonated when we shared it here back in April; and it was central to the shared vision that led to Anthropic’s acquisition of Mithril, & my joining the team. Why join Anthropic? Three reasons. (1) For Mithril, the programs continue, with more resources & infrastructure behind them, and as much Claude as I can put to work. (2) For me, the chance to start several more programs, & find out how many one person can actually run in parallel - an almost unprecedented luxury for a curious drug hunter. (3) For our mission, a path to institutionalize & scale this new way of working, then put it in the hands of all of biopharma, all over the world - which, candidly, I find the most energizing. Will AI x Bio cure diseases? Unequivocally yes, imo… but not by the route that gets the most airtime. Rather than timeline acceleration & compression, I see orchestration & parallelization as today's low-hanging fruit. Most drug hunters see a handful of go/no-go calls in a career, & spend entirely too much of the rest trading emails (my inbox can attest). Give them the bandwidth to run several programs at once, and the time to focus on scientific judgment, and I’m willing to bet they’ll make better calls. And at scale, better calls translate to more drugs, higher hit rates, broader patient impact, & likely, a disease or 10 or 100 cured. I couldn't be more excited to build toward that future @AnthropicAI. Finally, a heartfelt thank you to BioTwitter/X. The end of anonymity is bittersweet, but if anyone’s earned a proper introduction, you all have. It’s difficult to overstate how much this app has done for me: a decade of education, plenty of friends, many job opportunities, several mentors, a few investors, even a co-founder (fmr). It was the generosity of this community that inspired me to start posting 6 years ago, after just as many years lurking. I hope I’ve been able to pay it forward, in my own small way. But, to be clear, Prof Oak isn’t going anywhere. Same beat, same themes, and now, a front-row seat to drug development at the frontier. Stay tuned for dispatches from the trenches; and remember... Gotta Cure 'Em All

Aaron Edwards avatar
Aaron Edwards@aedwards02·Oct 22

Wink wink nudge nudge, the wealthiest are already going to China for their treatments 👀

On biotech and US-China competition, there will be a humbling moment in the US when the wealthiest people quietly start going to China for cutting-edge treatments. When the Saudi Floor at MGH moves to Shanghai. "They can cure this disease and we can't" impresses people in a way that GDP stats don't. Maybe then there will finally be some introspection here about exactly what we're getting wrong at the regulatory level.

Aaron Edwards avatar
Aaron Edwards@aedwards02·Oct 22

Exactly. Better instrumentation is essential, but so is making sense of the complexity it reveals. We’re building KiraLOGIC to interpret how multiplex edits interact to resist suppression & prioritize the best combos for scarce patient-derived models. Great piece, @amplesa!

Just read this -- explains nicely why AIxBio doesn't have an intelligence but an instrumentation problem

Ry Leahy avatar
⟳ Aaron Edwards retweeted
Ry Leahy@RySciComms·Oct 22

Bivalent CAR T-Cell Therapy Shows No Delayed Toxicity and Promising Survival in Recurrent Glioblastoma ascopost.com/issues/october-…